Robert Marcus
JPMorgan Chase & Co, Research Division
Good afternoon, everyone. I’m Robbie Marcus, the med tech analyst at JPMorgan. Really happy to have RxSight as our next presentation. CEO, Ron Kurtz will do a presentation followed by some Q&A. Ron?
Ronald Kurtz
President, CEO & Director
Thank you, Robbie. Appreciate being here again this year. These are our forward-looking statements.
RxSight is focused on transforming cataract surgery outcomes via the power of adjustability, and adjustability is a new capability that hasn’t existed in ophthalmology. We pioneered that over the last 5 years, and I’ll talk a little bit about how that is transforming cataract surgery and particularly, premium IOLs.
If we take a snapshot of RxSight today, over the past 5 years, we’ve grown to about 500 employees. We’ve performed about 300,000 LAL procedures. We have — we’re in about 1,100 ophthalmic offices with our piece of equipment that does the adjustment, the Light Delivery Device. We’ve trained over 2,500 surgeons and attained a market share of approximately 10% in the U.S. premium IOL market. And we have a strong balance sheet as well.
We did issue a press release now on Sunday and had a strong performance, good way to end the year, finished the year with about 12% year-over-year growth in procedures, increase in our installed base of nearly 20%. And perhaps most importantly, we announced our new Chief Financial Officer, Mark Wilterding. Very happy to have Mark onboard, comes with a wealth experience across different disciplines in med tech and banking, and he has hit the ground running here at JPMorgan. So welcome, Mark.
